Sebastian Attig
Overview
Explore the profile of Sebastian Attig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kuehnle M, Attig S, Britten C, Schulze-Bergkamen H, Lordick F, von Wichert G, et al.
Cancer Immunol Immunother
. 2014 Aug;
63(12):1273-84.
PMID: 25164876
Immunotherapeutic approaches are emerging as promising new treatment options for patients with solid cancers. The host immune system in cancer patients is dysfunctional due to a number of reasons. The...
12.
Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, et al.
Cancer Immunol Res
. 2014 Apr;
1(6):386-92.
PMID: 24778131
Vaccination with in vitro transcribed RNA encoding tumor antigens is an emerging approach in cancer immunotherapy. Attempting to further improve RNA vaccine efficacy, we have explored combining RNA with immunomodulators...
13.
Heinen A, Wanke F, Moos S, Attig S, Luche H, Pal P, et al.
Cytometry A
. 2014 Mar;
85(7):621-7.
PMID: 24616430
Staining of transcription factors (TFs) together with retention of fluorescent reporter proteins is hindered by loss of fluorescence using current available methods. In this study, it is shown that current...
14.
Diken M, Attig S, Grunwitz C, Kranz L, Simon P, van de Roemer N, et al.
Hum Vaccin Immunother
. 2013 Jul;
9(9):2025-32.
PMID: 23877042
The 11th Annual Meeting of Association for Cancer Immunotherapy (CIMT) welcomed more than 700 scientists around the world to Mainz, Germany and continued to be the largest immunotherapy meeting in...
15.
Filbert H, Attig S, Bidmon N, Renard B, Janetzki S, Sahin U, et al.
Cancer Immunol Immunother
. 2012 Nov;
62(4):615-27.
PMID: 23138872
Robust and sensitive ELISPOT protocols are commonly applied concomitant with the development of new immunotherapeutics. Despite the knowledge that individual serum batches differ in their composition and may change properties...
16.
Widenmeyer M, Griesemann H, Stevanovic S, Feyerabend S, Klein R, Attig S, et al.
Int J Cancer
. 2011 Aug;
131(1):140-9.
PMID: 21858810
CD4(+) T cells have been shown to be crucial for the induction and maintenance of cytotoxic T cell responses and to be also capable of mediating direct tumor rejection. Therefore,...
17.
Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Husemann Y, et al.
Cancer Res
. 2011 Aug;
71(19):6132-42.
PMID: 21816907
Intranodal immunization with antigen-encoding naked RNA may offer a simple and safe approach to induce antitumor immunity. RNA taken up by nodal dendritic cells (DC) coactivates toll-like receptor (TLR) signaling...
18.
Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, et al.
J Transl Med
. 2011 Jul;
9:108.
PMID: 21745365
Background: The introduction of antibody markers to identify undesired cell populations in flow-cytometry based assays, so called DUMP channel markers, has become a practice in an increasing number of labs...
19.
Attig S, Hennenlotter J, Pawelec G, Klein G, Koch S, Pircher H, et al.
Cancer Res
. 2009 Oct;
69(21):8412-9.
PMID: 19843860
Renal cell carcinoma is frequently infiltrated by cells of the immune system. This makes it important to understand interactions between cancer cells and immune cells so they can be manipulated...
20.
Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, et al.
Ann N Y Acad Sci
. 2007 Nov;
1114:23-35.
PMID: 17986574
The human immune system evolved to defend the organism against pathogens, but is clearly less well able to do so in the elderly, resulting in greater morbidity and mortality due...